Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Pu, Wang-Yang; Zhang, Rong; Xiao, Li; Wu, Yong-You; Gong, Wei; Lv, Xiao-Dong; Zhong, Feng-Yun; Zhuang, Zhi-Xiang; Bai, Xu-Ming; Li, Kai; Xing, Chun-Gen
• Is Part Of: BMC cancer. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 5
• Publication Date: 2016-12
• Subjects: Gastric cancer -- Circulating cell-free DNA -- DNA integrity -- Alu-qPCR; Cancer -- Periodicals; 616.994005
• DOI: 10.1186/s12885-016-2977-7
• Languages: English
• ISSNs: 1471-2407

Abstract

Abstract Background Circulating cell-free DNA (ccf-DNA) in plasma may contain both specific and non-specific of tumor markers. The concentration and integrity of ccf-DNA may be clinical useful for detecting and predicting cancer progression. Methods Plasma samples from 40 healthy controls and 73 patients with gastric cancers (two stage 0, 17 stage I, 11 stage II, 33 stage III, and 10 stage IV according to American Joint Committee on Cancer stage) were assessed respectively. qPCR targeting the Alu repeats was performed using two different sets of primers amplifying the long and short segments. DNA integrity was calculated as a ratio of the long to the short fragments of Alu repeats. Results Plasma DNA concentration was significantly higher in patients with stage III and IV gastric cancers than in healthy controls (p = 0.028 and 0.029 respectively). The receiver operating characteristic (ROC) curve for discriminating patients with stage III and IV gastric cancers from healthy controls had an area under the curve (AUC) of 0.744 (95% CI, 0.64 to 0.85). Circulating cell-free DNA concentration increased within 21 days following surgery and dropped by 3 months after surgery. Conclusions Concentration of ccf-DNA is a promising molecular marker for assessing gastric cancer progression. Trial registration Current Controlled TrialsChiCTR-DDT-12002848, 8 October 2012.